Deuterated or Partially Deuterated N,n-Dimethyltryptamine Compounds
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/EP2021/082227, filed Nov 18, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,251,371 | Deuterated or Partially Deuterated N,n-Dimethyltryptamine Compounds In force · High confidence | Cybin UK Ltd. | In force | High confidence | ||
| US 11,660,289 | Deuterated or Partially Deuterated N,n-Dimethyltryptamine Compounds In force · Medium confidence | Cybin UK Ltd. | In force | Medium confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.